

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-201036  
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-216656  
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-218772  
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-220170  
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-223636  
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-225554  
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-231272  
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-232304  
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-232774  
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-236149  
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-241675  
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-258778  
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-266781

*UNDER*

*THE SECURITIES ACT OF 1933*

---

**Bellicum Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

---

Delaware  
(State or other jurisdiction of  
incorporation or organization)

3730 Kirby Drive, Suite 1200  
Houston, TX  
(Address of principal executive offices)

20-1450200  
(I.R.S. Employer  
Identification No.)

77098  
(Zip Code)

2006 Stock Option Plan  
2011 Stock Option Plan  
2014 Equity Incentive Plan  
2014 Employee Stock Purchase Plan  
2019 Equity Incentive Plan  
(Full titles of the plans)

---

**Richard A. Fair**  
**President and Chief Executive Officer**  
**Bellicum Pharmaceuticals, Inc.**  
**3730 Kirby Drive, Suite 1200**  
**Houston, TX 77098**  
**(281) 454-3424**

**(Name, address, including zip code, and telephone number, including area code, of agent for service)**

*With copies to:*

**Matt Browne**  
**Cooley LLP**  
**10265 Science Center Drive**  
**San Diego, California 92121**  
**(858) 550-6000**

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input checked="" type="checkbox"/>	Smaller reporting company	<input checked="" type="checkbox"/>
		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

---

## DEREGISTRATION OF SECURITIES

These Post-Effective Amendments relate to the following Registration Statements on Form S-8 (each, a “**Registration Statement**” and, collectively, the “**Registration Statements**”), previously filed by Bellicum Pharmaceuticals, Inc., a Delaware corporation (the “**Company**”), with the U.S. Securities and Exchange Commission (the “**SEC**”):

- Registration Statement on Form S-8 (File No. 333-201036), originally filed with the SEC on December 18, 2014, pertaining to the registration of 167,056 shares of the Company’s common stock, \$0.01 par value per share (“**Common Stock**”), issuable under the Bellicum Pharmaceuticals, Inc. 2006 Stock Option Plan (the “**2006 Stock Option Plan**”), 2,449,090 shares of Common Stock issuable under the Bellicum Pharmaceuticals, Inc. 2011 Stock Option Plan (the “**2011 Stock Option Plan**”), 5,582,970 shares of Common Stock issuable under the Bellicum Pharmaceuticals, Inc. 2014 Equity Incentive Plan (the “**2014 Equity Incentive Plan**”) and 550,000 shares of Common Stock issuable under the Bellicum Pharmaceuticals, Inc. 2014 Employee Stock Purchase Plan (the “**2014 Employee Stock Purchase Plan**”);
  - Registration Statement on Form S-8 (File No. 333-216656), originally filed with the SEC on March 13, 2017, pertaining to the registration of an additional 500,000 shares of Common Stock issuable under the 2014 Equity Incentive Plan;
  - Registration Statement on Form S-8 (File No. 333-218772), originally filed with the SEC on June 15, 2017, pertaining to the registration of an additional 3,100,000 shares of Common Stock issuable under the 2014 Equity Incentive Plan;
  - Registration Statement on Form S-8 (File No. 333-220170), originally filed with the SEC on August 25, 2017, pertaining to the registration of an additional 145,000 shares of Common Stock issuable under the 2014 Equity Incentive Plan;
  - Registration Statement on Form S-8 (File No. 333-223636), originally filed with the SEC on March 13, 2018, pertaining to the registration of an additional 205,000 shares of Common Stock issuable under the 2014 Equity Incentive Plan;
  - Registration Statement on Form S-8 (File No. 333-225554), originally filed with the SEC on June 11, 2018, pertaining to the registration of an additional 130,000 shares of Common Stock issuable under the 2014 Equity Incentive Plan;
  - Registration Statement on Form S-8 (File No. 333-231272), originally filed with the SEC on May 8, 2019, pertaining to the registration of an additional 650,000 shares of Common Stock issuable under the 2014 Equity Incentive Plan;
  - Registration Statement on Form S-8 (File No. 333-232304), originally filed with the SEC on June 24, 2019, pertaining to the registration of 8,505,401 shares of Common Stock issuable under the Bellicum Pharmaceuticals, Inc. 2019 Equity Incentive Plan (the “**2019 Equity Incentive Plan**”);
  - Registration Statement on Form S-8 (File No. 333-232774), originally filed with the SEC on July 23, 2019, pertaining to the registration of an additional 500,000 shares of Common Stock issuable under the 2019 Equity Incentive Plan;
  - Registration Statement on Form S-8 (File No. 333-236149), originally filed with the SEC on January 29, 2020, pertaining to the registration of an additional 6,000,000 shares of Common Stock issuable under the 2019 Equity Incentive Plan;
  - Registration Statement on Form S-8 (File No. 333-241675), originally filed with the SEC on August 6, 2020, pertaining to the registration of an additional 800,000 shares of Common Stock issuable under the 2019 Equity Incentive Plan;
-

- Registration Statement on Form S-8 (File No. 333-258778), originally filed with the SEC on August 13, 2021, pertaining to the registration of an additional 500,000 shares of Common Stock issuable under the 2019 Equity Incentive Plan; and
- Registration Statement on Form S-8 (File No. 333-266781), originally filed with the SEC on August 11, 2022, pertaining to the registration of an additional 2,250,000 shares of Common Stock issuable under the 2019 Equity Incentive Plan.

On November 9, 2023, the Company's board of directors approved the liquidation and dissolution of the Company pursuant to a Plan of Dissolution (the "**Plan of Dissolution**"), and the Company's stockholders approved the Plan of Dissolution at the special meeting of the stockholders held on February 20, 2024.

In connection with the Plan of Dissolution, the Company is terminating any and all offerings of the Company's securities pursuant to its existing registration statements under the Securities Act of 1933, as amended, including the Registration Statements. In accordance with undertakings made by the Company in the Registration Statements to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance that remain unsold at the termination of the offering, the Company hereby removes from registration all such securities of the Company registered pursuant to the Registration Statements that remain unsold as of the date hereof. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Burlingame, State of California, on February 23, 2024.

**BELLICUM PHARMACEUTICALS, INC.**

By: /s/ Richard A. Fair

Name: Richard A. Fair

Title: *Principal Executive and Financial Officer*

No other person is required to sign these Post-Effective Amendments to the Registration Statements in reliance upon Rule 478 under the Securities Act of 1933, as amended.

---